NEW YORK – Castle Biosciences said after the close of the market on Tuesday that it has priced an underwritten public offering of 4 million shares of its common stock at $58 per share.
The company expects $232 million in gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses. In addition, Castle has granted the underwriters a 30-day option to purchase up to an additional 600,000 shares of common stock at the offering price. The offering is expected to close on or about December 18.